Valvular heart disease associated with fenfluramine-phentermine
Open accessThe DOI matches its Crossref record; 14 of the 14 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Fenfluramine and phentermine have been individually approved as anorectic agents by the Food and Drug Administration (FDA). When used in combination the drugs may be just as effective as either drug alone, with the added advantages of the need for lower doses of each agent and perhaps fewer side effects. Although the combination has not been approved by the FDA, in 1996 the total number of prescriptions in the United States for fenfluramine and phentermine exceeded 18 million. METHODS: We identified valvular heart disease in 24 women treated with fenfluramine-phentermine who had no history of cardiac disease. The women presented with cardiovascular symptoms or a heart murmur. As increasing numbers of these patients with similar clinical features were identified, there appeared to be an association between these features and fenfluramine-phentermine therapy. RESULTS: Twenty-four women (mean [+/-SD] age, 44+/-8 years) were evaluated 12.3+/-7.1 months after the initiation of fenfluramine-phentermine therapy. Echocardiography demonstrated unusual valvular morphology and regurgitation in all patients. Both right-sided and left-sided heart valves were involved. Eight women also had newly documented pulmonary hypertension. To date, cardiac surgical intervention has been required in five patients. The heart valves had a glistening white appearance. Histopathological findings included plaque-like encasement of the leaflets and chordal structures with intact valve architecture. The histopathological features were identical to those seen in carcinoid or ergotamine-induced valve disease. CONCLUSIONS: These cases arouse concern that fenfluramine-phentermine therapy may be associated with valvular heart disease. Candidates for fenfluramine-phentermine therapy should be informed about serious potential adverse effects, including pulmonary hypertension and valvular heart disease.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Early weight loss medications, such as fenfluramine (Fen-Phen) and sibutramine, were withdrawn due to severe cardiovascular and psychiatric side effects [3,4].”
From Obesity: Clinical Impact, Pathophysiology, Complications, and Modern Innovations in Therapeutic Strategies (2025) · cites this paper as [3]
In the citing paper
“While effective (average 10–15% weight loss), fenfluramine was withdrawn in 1997 after studies linked it to valvular heart disease and pulmonary hypertension [3].”
From Obesity: Clinical Impact, Pathophysiology, Complications, and Modern Innovations in Therapeutic Strategies (2025) · cites this paper as [3]
In the citing paper
“While effective (average 10–15% weight loss), fenfluramine was withdrawn in 1997 after studies linked it to valvular heart disease and pulmonary hypertension [3].”
From Obesity: Clinical Impact, Pathophysiology, Complications, and Modern Innovations in Therapeutic Strategies (2025) · cites this paper as [3]
In the citing paper
“Certainly, starvation, very-low-calorie diets, liquid protein diets, and obesity surgeries have been associated with prolongation of the QTc interval and increased risk of malignant dysrhythmias (1), and various pharmacologic agents have either limited efficacy or considerable toxicity (70 -72).”
From Obesity and Cardiovascular Disease (2009) · cites this paper as [70]
Citations
Cites
Appetite-suppressant drugs and the risk of primary pulmonary hypertension
Abenhaim, L., Moride, Y., Brenot, F., Rich, S., Benichou, J., Kurz, X., Higenbottam, T., Oakley, C., Wouters, E., Aubier, M., et al. (1996) · New England Journal of Medicine · doi:10.1056/nejm199608293350901 · Cited by 1,162
Carcinoid heart disease. Clinical and echocardiographic spectrum in 74 patients.
Pellikka, P. A., Tajik, A. J., Khandheria, B. K., Seward, J. B., Callahan, J. A., Pitot, H. C., & Kvols, L. K. (1993) · Circulation · doi:10.1161/01.cir.87.4.1188 · Cited by 614
Robiolio, P. A., Rigolin, V. H., Wilson, J. S., Harrison, J. K., Sanders, L. L., Bashore, T. M., & Feldman, J. M. (1995) · Circulation · doi:10.1161/01.cir.92.4.790 · Cited by 406
Doppler Echocardiography: Theory, Instrumentation, Technique, and Application
NISHIMURA, R. A., MILLER, F. A., CALLAHAN, M. J., BENASSI, R. C., SEWARD, J. B., & TAJIK, A. J. (1985) · Mayo Clinic Proceedings · doi:10.1016/s0025-6196(12)60540-0 · Cited by 263
Primary pulmonary hypertension and fenfluramine use.
Brenot, F., Herve, P., Petitpretz, P., Parent, F., Duroux, P., & Simonneau, G. (1993) · Heart · doi:10.1136/hrt.70.6.537 · Cited by 251
Weir, E. K., Reeve, H. L., Huang, J. M. C., Michelakis, E., Nelson, D. P., Hampl, V., & Archer, S. L. (1996) · Circulation · doi:10.1161/01.cir.94.9.2216 · Cited by 218
Klein, A. L., Burstow, D. J., Tajik, A. J., Zachariah, P. K., Taliercio, C. P., Taylor, C. L., Bailey, K. R., & Seward, J. B. (1990) · Journal of the American Society of Echocardiography · doi:10.1016/s0894-7317(14)80299-x · Cited by 213
Valve Disease Associated with Ergot Alkaloid Use: Echocardiographic and Pathologic Correlations
Redfield, M. M., Nicholson, W. J., Edwards, W. D., & Tajik, A. J. (1992) · Annals of Internal Medicine · doi:10.7326/0003-4819-117-1-50 · Cited by 156
Self-citationHormonal responses to fenfluramine in depressed and control subjects
Mitchell, P. B., & Smythe, G. A. (1990) · Journal of Affective Disorders · doi:10.1016/0165-0327(90)90008-v · Cited by 99
Irreversible pulmonary hypertension after treatment with fenfluramine.
McMurray, J. J. V., Bloomfield, P. M., & Miller, H. (1986) · BMJ · doi:10.1136/bmj.292.6515.239-a · Cited by 50
Research works printed but not linked: 4
- Heuer L, 1978, Chir Prax, 23, 497
- Tajik AJ, 1978, Mayo Clin Proc, 53, 271
- Thorson AH, 1958, Acta Med Scand Suppl, 334, 99
- Morita T, 1983, Am Rev Respir Dis, 127, 747
Cited by
Items 101–200 of 1,001
Kuypers, K. P., Ng, L., Erritzoe, D., Knudsen, G. M., Nichols, C. D., Nichols, D. E., Pani, L., Soula, A., & Nutt, D. (2019) · Journal of Psychopharmacology · doi:10.1177/0269881119857204 · Cited by 215
“The first example of this was the diet medication Phen/Fen, which had an unacceptably high fatality rate due to its effects on 5-HT2B receptors in the heart (Connolly et al., 1997).”
BackgroundValvular Heart Disease in Patients Taking Pergolide
Pritchett, A. M., Morrison, J. F., Edwards, W. D., Schaff, H. V., Connolly, H. M., & Espinosa, R. E. (2002) · Mayo Clinic Proceedings · doi:10.4065/77.12.1280 · Cited by 222
Self-citationWeissman, N. J., Tighe, J. F., Gottdiener, J. S., & Gwynne, J. T. (1998) · New England Journal of Medicine · doi:10.1056/nejm199809103391103 · Cited by 223
Aortic valve disease and treatment: The need for naturally engineered solutions
Butcher, J. T., Mahler, G. J., & Hockaday, L. A. (2011) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2011.01.008 · Cited by 210
Potenza, M. N., Holmes, J. P., Kanes, S. J., & McDougle, C. J. (1999) · Journal of Clinical Psychopharmacology · doi:10.1097/00004714-199902000-00008 · Cited by 220
Strategies to Discover Unexpected Targets for Drugs Active at G Protein–Coupled Receptors
Allen, J. A., & Roth, B. L. (2011) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev-pharmtox-010510-100553 · Cited by 216
The obesity pipeline: current strategies in the development of anti-obesity drugs
Cooke, D., & Bloom, S. (2006) · Nature Reviews Drug Discovery · doi:10.1038/nrd2136 · Cited by 211
Carbonic anhydrase inhibitors as emerging drugs for the treatment of obesity
Supuran, C. T., Fiore, A. D., & Simone, G. D. (2008) · Expert Opinion on Emerging Drugs · doi:10.1517/14728214.13.2.383 · Cited by 216
BMPR2 germline mutations in pulmonary hypertension associated with fenfluramine derivatives
Humbert, M., Deng, Z., Simonneau, G., Barst, R. J., Sitbon, O., Wolf, M., Cuervo, N., Moore, K. J., Hodge, S. E., Knowles, J. A., et al. (2002) · European Respiratory Journal · doi:10.1183/09031936.02.01762002 · Cited by 211
Finding New Tricks For Old Drugs: An Efficient Route For Public-Sector Drug Discovery
O'Connor, K. A., & Roth, B. L. (2005) · Nature Reviews Drug Discovery · doi:10.1038/nrd1900 · Cited by 215
Rothman, R. B., Ayestas, M. A., Dersch, C. M., & Baumann, M. H. (1999) · Circulation · doi:10.1161/01.cir.100.8.869 · Cited by 213
Pulmonary Arterial Hypertension: Pathophysiology and Anesthetic Approach
Blaise, G., Langleben, D., & Hubert, B. (2003) · Anesthesiology · doi:10.1097/00000542-200312000-00027 · Cited by 211
The promises and perils of psychedelic pharmacology for psychiatry
McClure-Begley, T. D., & Roth, B. L. (2022) · Nature Reviews Drug Discovery · doi:10.1038/s41573-022-00421-7 · Cited by 194
Gardin, J. M. (2000) · JAMA · doi:10.1001/jama.283.13.1703 · Cited by 206
The regulation of food intake by the gut-brain axis: implications for obesity
Hussain, S. S., & Bloom, S. R. (2013) · International Journal of Obesity · doi:10.1038/ijo.2012.93 · Cited by 195
Appetite regulation: from the gut to the hypothalamus
Neary, N. M., Goldstone, A. P., & Bloom, S. R. (2004) · Clinical Endocrinology · doi:10.1046/j.1365-2265.2003.01839.x · Cited by 193
Sohn, J.-W., Xu, Y., Jones, J. E., Wickman, K., Williams, K. W., & Elmquist, J. K. (2011) · Neuron · doi:10.1016/j.neuron.2011.06.012 · Cited by 196
5‐HYDROXYTRYPTAMINE IN THE CARDIOVASCULAR SYSTEM: FOCUS ON THE SEROTONIN TRANSPORTER (SERT)
Ni, W., & Watts, S. W. (2006) · Clinical and Experimental Pharmacology and Physiology · doi:10.1111/j.1440-1681.2006.04410.x · Cited by 189
Anti-obesity therapy: from rainbow pills to polyagonists
Müller, T. D., Clemmensen, C., Finan, B., DiMarchi, R. D., & Tschöp, M. H. (2018) · Pharmacological Reviews · doi:10.1124/pr.117.014803 · Cited by 199
“…clinical reports emerged linking fenfluramine and dexfenfluramine to the development of pulmonary hypertension and valvular heart disease (Cannistra et al., 1997; Centers for Disease Control and Prevention (CDC), 1997; Connolly et al., 1997; Kurz and Van Ermen, 1997; Rasmussen et al., 1997).”
BackgroundInfluentialBonow, R. O., Carabello, B. A., Chatterjee, K., de Leon, A. C., Faxon, D. P., Freed, M. D., Gaasch, W. H., Lytle, B. W., Nishimura, R. A., O’Gara, P. T., et al. (2006) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2006.05.030 · Cited by 198
White Paper AGA: POWER — Practice Guide on Obesity and Weight Management, Education, and Resources
Acosta, A., Streett, S., Kroh, M. D., Cheskin, L. J., Saunders, K. H., Kurian, M., Schofield, M., Barlow, S. E., & Aronne, L. (2017) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2016.10.023 · Cited by 191
Factors involved in white‐to‐brown adipose tissue conversion and in thermogenesis: a review
Montanari, T., Pošćić, N., & Colitti, M. (2017) · Obesity Reviews · doi:10.1111/obr.12520 · Cited by 188
Antiobesity Pharmacotherapy: New Drugs and Emerging Targets
Kim, G. W., Lin, J. E., Blomain, E. S., & Waldman, S. A. (2013) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2013.204 · Cited by 191
Heal, D. J., Smith, S. L., Fisas, A., Codony, X., & Buschmann, H. (2008) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2007.08.006 · Cited by 184
Carcinoid A Comprehensive Review
Schnirer, I. I., Yao, J. C., & Ajani, J. A. (2003) · Acta Oncologica · doi:10.1080/02841860310010547 · Cited by 192
Central Serotonin and Melanocortin Pathways Regulating Energy Homeostasis
HEISLER, L. K., COWLEY, M. A., KISHI, T., TECOTT, L. H., FAN, W., LOW, M. J., SMART, J. L., RUBINSTEIN, M., TATRO, J. B., ZIGMAN, J. M., et al. (2003) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.2003.tb03177.x · Cited by 187
Serotonin Mechanisms in Heart Valve Disease I
Jian, B., Xu, J., Connolly, J., Savani, R. C., Narula, N., Liang, B., & Levy, R. J. (2002) · The American Journal of Pathology · doi:10.1016/s0002-9440(10)64489-6 · Cited by 182
Hildebrandt, A. L., Kelly-Sullivan, D. M., & Black, S. C. (2003) · European Journal of Pharmacology · doi:10.1016/s0014-2999(03)01343-8 · Cited by 181
Body weight is regulated by the brain: a link between feeding and emotion
Kishi, T., & Elmquist, J. K. (2005) · Molecular Psychiatry · doi:10.1038/sj.mp.4001638 · Cited by 178
Psaty, B. M. (1999) · JAMA · doi:10.1001/jama.282.8.786 · Cited by 187
Therapeutic and adverse actions of serotonin transporter substrates
Rothman, R. B., & Baumann, M. H. (2002) · Pharmacology & Therapeutics · doi:10.1016/s0163-7258(02)00234-6 · Cited by 183
“These drugs were widely prescribed for the treatment of obesity until they were withdrawn from the market in September 1997 due to reports of cardiac valvulopathy (Connolly et al., 1997; Connolly & McGoon, 1999).”
BackgroundDopamine transporter imaging with [123I]FP-CIT SPECT: potential effects of drugs
Booij, J., & Kemp, P. (2008) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-007-0621-0 · Cited by 175
Research Units on Pediatric Psychopharmacology (Rupp) Autism Network
McDougle, C. J., Scahill, L., McCracken, J. T., Aman, M. G., Tierney, E., Arnold, L. E., Freeman, B. J., Martin, A., McGough, J. J., Cronin, P., et al. (2000) · Child and Adolescent Psychiatric Clinics of North America · doi:10.1016/s1056-4993(18)30142-1 · Cited by 179
Obesity: An overview on its current perspectives and treatment options
Nammi, S., Koka, S., Chinnala, K. M., & Boini, K. M. (2004) · Nutrition Journal · doi:10.1186/1475-2891-3-3 · Cited by 165
FDA-Approved Anti-Obesity Drugs in the United States
Daneschvar, H. L., Aronson, M. D., & Smetana, G. W. (2016) · The American Journal of Medicine · doi:10.1016/j.amjmed.2016.02.009 · Cited by 170
The Epidemiology of Valvular Heart Disease: a Growing Public Health Problem
Supino, P. G., Borer, J. S., Preibisz, J., & Bornstein, A. (2006) · Heart Failure Clinics · doi:10.1016/j.hfc.2006.09.010 · Cited by 172
Direct-to-Consumer Marketing of Prescription Drugs: Creating Consumer Demand
Hollon, M. F. (1999) · JAMA · doi:10.1001/jama.281.4.382 · Cited by 174
Kotloff, K. L., Corretti, M., Palmer, K., Campbell, J. D., Reddish, M. A., Hu, M. C., Wasserman, S. S., & Dale, J. B. (2004) · JAMA · doi:10.1001/jama.292.6.709 · Cited by 173
Onakpoya, I. J., Heneghan, C. J., & Aronson, J. K. (2016) · BMC Medicine · doi:10.1186/s12916-016-0735-y · Cited by 171
Anorectics on Trial: A Half Century of Federal Regulation of Prescription Appetite Suppressants
Colman, E. (2005) · Annals of Internal Medicine · doi:10.7326/0003-4819-143-5-200509060-00013 · Cited by 167
Long-term Pharmacotherapy of Obesity 2000: A Review of Efficacy and Safety
Glazer, G. (2001) · Archives of Internal Medicine · doi:10.1001/archinte.161.15.1814 · Cited by 170
“A serotonergic mechanism for anorectic valvulopathy was strongly suggested as early as the initial report by Connolly et al.69 Specifically, endocardial fibroplasia seen inheart valves removed from anorectic-exposed patients was described as indistinguishable from the pathologic changes unique to carcinoid syndrome (s…”
ResultData Resource Profile: The French National Uniform Hospital Discharge Data Set Database (PMSI)
Boudemaghe, T., & Belhadj, I. (2016) · International Journal of Epidemiology · doi:10.1093/ije/dyw359 · Cited by 167
Cheung, B. M. Y., Cheung, T. T., & Samaranayake, N. R. (2013) · Therapeutic Advances in Drug Safety · doi:10.1177/2042098613489721 · Cited by 159
Dinitrophenol and obesity: an early twentieth-century regulatory dilemma
Colman, E. (2007) · Regulatory Toxicology and Pharmacology · doi:10.1016/j.yrtph.2007.03.006 · Cited by 160
SIRT1 Deacetylase in SF1 Neurons Protects against Metabolic Imbalance
Ramadori, G., Fujikawa, T., Anderson, J., Berglund, E. D., Frazao, R., Michán, S., Vianna, C. R., Sinclair, D. A., Elias, C. F., & Coppari, R. (2011) · Cell Metabolism · doi:10.1016/j.cmet.2011.06.014 · Cited by 158
Douketis, J. D., Feightner, J., Attia, J. R., & Feldman, W. F. (1999) · Europe PMC (PubMed Central) · Cited by 195
Pregnancy after adjustable gastric banding*1
MARTIN, L. (2000) · Obstetrics & Gynecology · doi:10.1016/s0029-7844(00)00819-x · Cited by 152
Posey, D. J., Guenin, K. D., Kohn, A. E., Swiezy, N. B., & McDougle, C. J. (2001) · Journal of Child and Adolescent Psychopharmacology · doi:10.1089/10445460152595586 · Cited by 156
Toward a broader view of mechanisms of drug cardiotoxicity
Mamoshina, P., Rodríguez, B., & Bueno‐Orovio, A. (2021) · Cell Reports Medicine · doi:10.1016/j.xcrm.2021.100216 · Cited by 167
Peters, J., Schnider, P., Mattei, P., & Kansy, M. (2009) · ChemMedChem · doi:10.1002/cmdc.200800411 · Cited by 150
Treatment of Obese Adolescents with Sibutramine: A Randomized, Double-Blind, Controlled Study
Godoy-Matos, A., Carraro, L., Vieira, A., Oliveira, J., Guedes, E. P., Mattos, L., Rangel, C., Moreira, R. O., Coutinho, W., & Appolinario, J. C. (2005) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2004-0263 · Cited by 158
Sibutramine: A Serotonin–Norepinephrine Reuptake-Inhibitor for the Treatment of Obesity
Luque, C. A., & Rey, J. A. (1999) · Annals of Pharmacotherapy · doi:10.1345/aph.18319 · Cited by 155
Safety of Drug Therapies Used for Weight Loss and Treatment of Obesity
Ioannides‐Demos, L. L., Proietto, J., Tonkin, A. M., & McNeil, J. J. (2006) · Drug Safety · doi:10.2165/00002018-200629040-00001 · Cited by 169
Centrally Acting Agents for Obesity: Past, Present, and Future
Coulter, A. A., Rebello, C. J., & Greenway, F. L. (2018) · Drugs · doi:10.1007/s40265-018-0946-y · Cited by 151
“Shortly after, however, 24 women with previously normal hearts developed heart murmurs after taking fenfluramine, and at surgery had left-sided valvular lesions that resembled the right-sided heart valve lesions commonly associated with carcinoid syndrome [14].”
Higgins, G. A., Silenieks, L. B., Rossmann, A., Rizos, Z., Noble, K., Soko, A. D., & Fletcher, P. J. (2011) · Neuropsychopharmacology · doi:10.1038/npp.2011.303 · Cited by 157
“Unfortunately its subsequent withdrawal owing to cardiac valvulopathy and pulmonary hypertension (Connolly et al, 1997) highlighted clinical complications associated with the indiscriminate activation of this neurotransmitter system.”
BackgroundBenfluorex and valvular heart disease: a cohort study of a million people with diabetes mellitus
Weill, A., Païta, M., Tuppin, P., Fagot, J., Neumann, A., Simon, D., Ricordeau, P., Montastruc, J., & Allemand, H. (2010) · Pharmacoepidemiology and Drug Safety · doi:10.1002/pds.2044 · Cited by 158
Tucker, G. T. (2000) · The Lancet · doi:10.1016/s0140-6736(00)02047-x · Cited by 151
Huang, X., Setola, V., Yadav, P. N., Allen, J., Rogan, S. C., Hanson, B. J., Revankar, C. M., Robers, M., Doucette, C., & Roth, B. L. (2009) · Molecular Pharmacology · doi:10.1124/mol.109.058057 · Cited by 152
“Because duration of therapy with VHD- associated drugs is an important determinant of valvulopathic risk (Connolly et al., 1997; Roth, 2007; Schade et al., 2007), the short-term use of xylometazoline and oxymetazoline (nasal decongestants) and the one-time use of fenoldopam (antihypertensive agent…”
BackgroundPharmacological Therapies for Obesity
Kaplan, L. M. (2005) · Gastroenterology Clinics of North America · doi:10.1016/j.gtc.2004.12.002 · Cited by 149
Pharmacology of stimulants prohibited by the World Anti‐Doping Agency (WADA)
Docherty, J. (2008) · British Journal of Pharmacology · doi:10.1038/bjp.2008.124 · Cited by 131
Endothelium-Dependent Regulation of the Mechanical Properties of Aortic Valve Cusps
El-Hamamsy, I., Balachandran, K., Yacoub, M. H., Stevens, L., Sarathchandra, P., Taylor, P. M., Yoganathan, A. P., & Chester, A. H. (2009) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2008.11.056 · Cited by 165
Measuring Endogenous 5-HT Release by Emission Tomography: Promises and Pitfalls
Paterson, L. M., Tyacke, R. J., Nutt, D. J., & Knudsen, G. M. (2010) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1038/jcbfm.2010.104 · Cited by 145
“Fenfluramine, despite being an efficient way to increase 5-HT in animals, cannot readily be administered to human subjects in high doses (Connolly et al, 1997), although one study has now published preliminary findings using an oral dose to increase brain 5-HT (Hasler et al, 2009).”
ResultFood Ingredients as Anti-Obesity Agents: A Review
Trigueros, L., Peña, S., Ugidos, A. V., Sayas‐Barberá, E., Pérez‐Álvarez, J. Á., & Sendra, E. (2013) · Critical Reviews in Food Science and Nutrition · doi:10.1080/10408398.2011.574215 · Cited by 160
Pharmacological Therapy of Obesity: Past, Present, and Future
Weigle, D. S. (2003) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2003-030151 · Cited by 148
Clifton, P. G., Lee, M. D., & Dourish, C. T. (2000) · Psychopharmacology · doi:10.1007/s002130000504 · Cited by 147
Drug-induced fibrotic valvular heart disease
Bhattacharyya, S., Schapira, A. H. V., Mikhailidis, D. P., & Davar, J. (2009) · The Lancet · doi:10.1016/s0140-6736(09)60252-x · Cited by 162
Worldwide perspective of valve disease
Soler-Soler, J., & Galve, E. (2000) · Heart · doi:10.1136/heart.83.6.721 · Cited by 146
Pharmacological Treatment of Obesity: Therapeutic Strategies
Kordik, C. P., & Reitz, A. B. (1999) · Journal of Medicinal Chemistry · doi:10.1021/jm980521l · Cited by 153
Serotonergic drugs and valvular heart disease
Rothman, R. B., & Baumann, M. H. (2009) · Expert Opinion on Drug Safety · doi:10.1517/14740330902931524 · Cited by 139
Serotonin and energy balance: molecular mechanisms and implications for type 2 diabetes
Lam, D. D., & Heisler, L. K. (2007) · Expert Reviews in Molecular Medicine · doi:10.1017/s1462399407000245 · Cited by 142
Himmerich, H., Lewis, Y. D., Conti, C. M., Mutwalli, H., Karwautz, A. F. K., Sjögren, J. M., Uribe-Isaza, M. M., Tyszkiewicz‐Nwafor, M., Aigner, M., McElroy, S. L., et al. (2023) · The World Journal of Biological Psychiatry · doi:10.1080/15622975.2023.2179663 · Cited by 154
The maintenance of treatment effects in the long-term management of obesity.
Perri, M. G. (1998) · Clinical Psychology: Science and Practice · doi:10.1111/j.1468-2850.1998.tb00172.x · Cited by 141
Gustafsson, B. I., Hauso, Ø., Drozdov, I. A., Kidd, M. S., & Modlin, I. M. (2008) · International Journal of Cardiology · doi:10.1016/j.ijcard.2008.02.019 · Cited by 148
Milk Protein Hydrolysates and Bioactive Peptides
Nongonierma, A. B., O’Keeffe, M. B., & Fitzgerald, R. J. (2015) · Springer eBooks · doi:10.1007/978-1-4939-2800-2_15 · Cited by 154
Potential drug targets for calcific aortic valve disease
Hutcheson, J. D., Aïkawa, E., & Merryman, W. D. (2014) · Nature Reviews Cardiology · doi:10.1038/nrcardio.2014.1 · Cited by 150
RISK FACTORS FOR PULMONARY ARTERIAL HYPERTENSION
Humbert, M. J. C., Nunès, H., Sitbon, O., Parent, F., Hervé, P., & Simonneau, G. (2001) · Clinics in Chest Medicine · doi:10.1016/s0272-5231(05)70284-7 · Cited by 139
Toxicity of Weight Loss Agents
Yen, M., & Ewald, M. B. (2012) · Journal of Medical Toxicology · doi:10.1007/s13181-012-0213-7 · Cited by 147
Zuetenhorst, J. M., Bonfrer, J. M. G. M., Korse, C. M., Bakker, R., van Tinteren, H., & Taal, B. G. (2003) · Cancer · doi:10.1002/cncr.11226 · Cited by 126
The surgical treatment of morbid obesity
Kellum, J. M., DeMaria, E. J., & Sugerman, H. J. (1998) · Current Problems in Surgery · doi:10.1016/s0011-3840(98)80009-9 · Cited by 151
Drug, Patient, and Physician Characteristics Associated With Off-label Prescribing in Primary Care
Eguale, T., Buckeridge, D. L., Winslade, N. E., Benedetti, A., Hanley, J. A., & Tamblyn, R. M. (2012) · Archives of Internal Medicine · doi:10.1001/archinternmed.2012.340 · Cited by 160
“Indeed, off-label use of fenfluramine-phentermine was shown to cause cardiac valve damage.(2,3) When tiagabine, a drug approved to treat partial seizures, was used off-label to treat psychiatric conditions, seizuresandstatusepilepticus occurred.”
BackgroundKars, M., Delgado, V., Holman, E. R., Feelders, R. A., Smit, J. W. A., Romijn, J. A., Bax, J. J., & Pereira, A. M. (2008) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2007-2658 · Cited by 138
Simula, D. V., Edwards, W. D., Tazelaar, H. D., Connolly, H. M., & Schaff, H. V. (2002) · Mayo Clinic Proceedings · doi:10.4065/77.2.139 · Cited by 135
Self-citationDrug-induced Valvulopathy: An Update
Elangbam, C. S. (2010) · Toxicologic Pathology · doi:10.1177/0192623310378027 · Cited by 133
Rothman, R. B., & Baumann, M. H. (2002) · Pharmacology Biochemistry and Behavior · doi:10.1016/s0091-3057(01)00669-4 · Cited by 140
Murphy, D. L., Andrews, A. M., Wichems, C. H., Li, Q., Tohda, M., & Greenberg, B. D. (1998) · PubMed · Cited by 164
Potential Effect of Authorization Bias on Medical Record Research
Jacobsen, S. J., Xia, Z., Campion, M. E., Darby, C. H., Plevak, M. F., Seltman, K. D., & Melton, L. J. (1999) · Mayo Clinic Proceedings · doi:10.4065/74.4.330 · Cited by 132
Kulke, M. H., O’Dorisio, T. M., Phan, A. T., Bergsland, E. K., Law, L., Banks, P. L., Freiman, J. P., Frazier, K., Jackson, J. R., Yao, J. C., et al. (2014) · Endocrine Related Cancer · doi:10.1530/erc-14-0173 · Cited by 130
Cardiac valves and valvular pathology
Schöen, F. J. (2005) · Cardiovascular Pathology · doi:10.1016/j.carpath.2005.03.005 · Cited by 130
Carcinoid Tumors and Fibrosis: An Association with No Explanation
Modlin, I. M., Shapiro, M. D., & Kidd, M. (2004) · The American Journal of Gastroenterology · doi:10.1111/j.1572-0241.2004.40507.x · Cited by 130
“Support for the role of serotonin in valvulopathy has been described after prolonged administration of the diet drug combination of fenfluramine–phentermine”
BackgroundPrevalence and correlates of aortic regurgitation in american indians: the Strong Heart Study
Lebowitz, N. E., Bella, J. N., Roman, M. J., Liu, J. E., Fishman, D. P., Paranicas, M., Lee, E. T., Fabsitz, R. R., Welty, T. K., Howard, B. V., et al. (2000) · Journal of the American College of Cardiology · doi:10.1016/s0735-1097(00)00744-0 · Cited by 128
Aminorex to Fen/Phen: An Epidemic Foretold
Fishman, A. P. (1999) · Circulation · doi:10.1161/01.cir.99.1.156 · Cited by 130
The discovery and status of sibutramine as an anti-obesity drug
Luque, C. A., & Rey, J. A. (2002) · European Journal of Pharmacology · doi:10.1016/s0014-2999(02)01423-1 · Cited by 128
A concise review on the therapeutics of obesity
Bray, G. A. (2000) · Nutrition · doi:10.1016/s0899-9007(00)00424-x · Cited by 143
Lifestyle and Pharmacological Approaches to Weight Loss: Efficacy and Safety
Bray, G. A. (2008) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2008-1294 · Cited by 123
Behavioral and pharmacologic therapies for obesity
Vetter, M. L., Faulconbridge, L. F., Webb, V. L., & Wadden, T. A. (2010) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2010.121 · Cited by 123
Effects of Obesity and Weight Loss on Cardiac Function and Valvular Performance
Karason, K., Wallentin, I., Larsson, B., & Sjöströmt, L. (1998) · Obesity Research · doi:10.1002/j.1550-8528.1998.tb00374.x · Cited by 126
Grewal, J. S., Mukhin, Y. V., Garnovskaya, M. N., Raymond, J. R., & Greene, E. L. (1999) · American Journal of Physiology-Renal Physiology · doi:10.1152/ajprenal.1999.276.6.f922 · Cited by 124
Dangol, M., Kim, S., Li, C. G., Lahiji, S. F., Jang, M., Ma, Y., Huh, I., & Jung, H. (2017) · Journal of Controlled Release · doi:10.1016/j.jconrel.2017.03.400 · Cited by 125
“However, these drugs have severe multiple side effects including stroke, suicidal tendency, and depression [8].”
BackgroundOntogeny and regulation of the serotonin transporter: Providing insights into human disorders
Daws, L. C., & Gould, G. G. (2011) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2011.03.013 · Cited by 116
““Fenfen” was found to produce heart valve disease via a 5-HT-induced fibrotic reaction, in which collagen fiber overgrowth, coats and thickens the heart valves leading to cardiac malfunction from valve leakage and regurgitation (Connolly et al., 1997; Gardin et al., 2000; Jick 2000; Soler-Soler and Galve, 2000).”
BackgroundUpdates on obesity pharmacotherapy
Velazquez, A., & Apovian, C. M. (2018) · Annals of the New York Academy of Sciences · doi:10.1111/nyas.13542 · Cited by 115
Metadata
- Authors
- Connolly, H. M., Crary, J. L., McGoon, M. D., Hensrud, D. D., Edwards, B. S., Edwards, W. D., & Schaff, H. V.
- Affiliations
- Mayo Clinic (US)
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 1997-08-28
- Volume
- 337
- Issue
- 9
- Pages
- 581-588
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2134362869
- Cited by
- 1,632
- References
- 14
- Citations by year
- 2026: 23 · 2025: 23 · 2024: 26 · 2023: 43 · 2022: 32 · 2021: 40 · 2020: 35 · 2019: 39 · 2018: 42 · 2017: 55 · 2016: 54 · 2015: 58 · 2014: 51 · 2013: 55 · 2012: 59
- FWCI
- 72.34
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Cardiac Valve Diseases and Treatments
- Health Sciences › Medicine › Pharmacology (medical) › Pharmacology and Obesity Treatment
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Cardiovascular Issues in Pregnancy
- Keywords
- valvular heart disease, pulmonary hypertension, anorectic agents, women, adverse drug reactions
- MeSH terms
- Adult, Aortic Valve Insufficiency, Appetite Depressants, Drug Combinations, Female, Fenfluramine, Heart Valve Diseases, Humans, Hypertension, Pulmonary, Middle Aged, Mitral Valve, Mitral Valve Insufficiency, Phentermine, Tricuspid Valve Insufficiency, Ultrasonography
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.